source
- Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchiseAlnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…
- Cardinal Health issues updated instructions for Presource kits containing recalled BD Alaris infusion setsThe FDA CDRH issued an Early Alert to inform the public of a potentially high‑risk device issue involving Cardinal Health Presource kits that may contain BD Alaris Pump Infusion Sets linked to a re…